CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sun Pharmaceutical Industries Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sun Pharmaceutical Industries Ltd
Sun House, CTS No. 201 B/1,, Western Exp
Phone: +91 2243244324p:+91 2243244324 MUMBAI, 400 093  India Ticker: SUNPHARMASUNPHARMA
Business Summary
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. It is engaged in manufacturing, developing, and marketing a range of branded and generic formulations and active pharmaceutical ingredients (APIs). It produces a diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its global specialty portfolio spans advanced products in dermatology, ophthalmology, and onco-dermatology. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its vertically integrated operations deliver medicines to physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes--YesYes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman, Managing Director, Executive Director Dilip S.Shanghvi 68 5/22/2024 3/1/1993
Chief Financial Officer C. S.Muralidharan 6/19/2017 6/19/2017
Whole-time Director, Executive Vice-President, Emerging Markets, Global generic R&D, Global BD (Gen Aalok D.Shanghvi 40 6/1/2023 6/1/2023
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Taro Pharmaceutical Industries Ltd 14 Hakitor Street, HAIFA Israel
Ranbaxy Laboratories Limited Village Toansa, Rail Majra NAWANSHAHR India
Ranbaxy Laboratories Limited (ADR) Village Toansa, Rail Majra Nawanshahr India
8 additional Subsidiary records available in full report.

Business Names
Business Name
3 Skyline LLC
524715
Aditya Acquisition Company Ltd.
87 additional Business Names available in full report.

General Information
Number of Employees: 43,000 (As of 3/31/2024)
Outstanding Shares: 2,399,334,970 (As of 9/30/2024)
Shareholders: 653,134
Stock Exchange: NSE
Fax Number: +91 2243244343


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024